Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for cognitive function and neuroinflammation in NASH
2020-004373-50Phase 2Terminated
- Sponsor
- Aarhus University Hospital
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Change in cognitive function (PHES). Started Dec 2020; status: terminated.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2020-004373-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004373-50.